Sanofi has become the latest big pharma company to boost manufacturing in the US with a hefty investment as the biopharma industry safeguards itself against the continued threat of pharma tariffs ...

We came across a bullish thesis on Sanofi (SNY) on Substack by Business Model Mastery. In this article, we will summarize the bulls’ thesis on SNY. Sanofi (SNY)'s share was trading at $51.06 as ...

Sanofi has returned to Nurix Therapeutics for another autoimmune candidate, paying $15 million and committing up to $465 million for exclusive rights to a degrader of a once-undruggable ...

I'll start by comparing the revenue growth rates of AbbVie and Sanofi, then move on to discuss how often these two leaders in the autoimmune disease treatment market beat Wall Street analysts ...

Sanofi confirmed on Monday plans to sell a controlling stake in its over-the-counter unit to a US investment fund, after employment and investment guarantees relieved political controversy. The ...

Sanofi carries out more than 60 percent of its global production in the European Union. (Image Credits: Reuters) Sanofi Healthcare India Pvt. Ltd. (SHIPL) on Wednesday announced the expansion of ...

As Sanofi strives to become a global immunology leader, it's also busy making the most of a crucial immunization rollout with partner AstraZeneca. On both fronts, Sanofi expects to see dividends ...

Sanofi is buying Inhibrx in a $1.7 billion deal as the French pharmaceutical giant expands its pipeline of drugs that can treat rare diseases. The agreement will give Sanofi access to Inhibrx's ...

Wallpaper Engine isn’t just a sensationally good value; it’s just plain sensational. This brilliant app offers access to a sprawling collection of user-made animated wallpapers, and its ...

We have just scratched the surface as to how we embrace these disruptive technologies to achieve our ambition of transforming the practice of medicine”, Paul Hudson, CEO of Sanofi. In under two ...

Sanofi is rolling out its artificial intelligence app, Plai, as it doubles down on its efforts to incorporate AI throughout its research and development activities. The app, developed in partnership ...

Sanofi is reducing the price of its most important insulin product. A pending acquisition could help pick up the slack in diabetes care. Sanofi's business extends beyond its diabetes-related ...